STAAR Surgical supplements proxy for Alcon merger; faces lawsuits, Broadwood opposition

STAAR SURGICAL CO

Two shareholder lawsuits filed Oct 1 in NY state court alleging proxy misrepresentations; demand letters also received.
STAAR voluntarily supplements proxy with additional disclosure; believes claims without merit but seeks to avoid delay.
Broadwood (27.3% holder) opposes merger; Soleus (6%) supports; Yunqi (5.1%) opposes. No competing proposals received.
Special meeting to vote on merger scheduled Oct 23, 2025; $28.00 per share consideration unchanged.
Citi's DCF analysis implied per share range $17.70-$37.50; selected precedent transactions EV/LTM revenue 3.1x-6.3x.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.